A Research Guide for
Facing Lewy Body Dementia

🕑 Your First 90 Days — A Dated Action Clock

LBD care follows a logical order. Use this time-phased checklist with your medical team. The dates are targets, not deadlines — move faster if symptoms are severe.

Within the first week

• Get the antipsychotic-sensitivity alert onto your chart. Ask your neurologist: “Will you flag severe neuroleptic sensitivity as an allergy in my medical record and list the specific drugs to avoid?”
• Have every current medication reviewed for anticholinergic and dopamine-blocking drugs (see Medications to Avoid).
• Set up bedroom safety if there is dream-enactment (RBD): remove sharp objects, pad the floor, consider a mattress on the floor.

Within two weeks

• Begin a cholinesterase inhibitor trial if cognition or hallucinations are affecting daily life. Ask: “Should I start rivastigmine or donepezil, and would the patch be easier to tolerate?”
• For dream-enactment, ask about melatonin first. Ask: “Can we try melatonin at bedtime before anything stronger for my REM sleep behavior disorder?”

In the first month

• Give the cholinesterase inhibitor a fair trial period. These medicines usually need about 3 months before you can tell whether they help. When to stop: only with your neurologist, and by tapering — never stop a cholinesterase inhibitor abruptly, because cognition can drop rapidly.
• If hallucinations are distressing, ask about pimavanserin or very low-dose quetiapine. Ask: “Are my hallucinations bothering me enough to treat, and is pimavanserin an option for me?”

By month 3

• Reassess motor symptoms. If parkinsonism limits you, ask about the lowest effective dose of carbidopa/levodopa. The dose should not keep being raised if hallucinations or confusion worsen — discontinue further increases and step back to the last tolerated dose.
• Confirm referral to a movement-disorder or behavioral neurologist if you are not already seeing one.
• Complete advance directives and healthcare power of attorney while participation is easiest.

💰 What LBD Medications Cost

The good news: nearly every core LBD medication is an inexpensive generic. The figures below use the U.S. government’s average pharmacy acquisition cost (CMS NADAC, from the file dated July 15, 2026) for a rough 30-day supply. Cash prices at the counter run a little higher, but these are among the cheapest prescriptions in medicine.

• Donepezil 10 mg once daily — about $1–$2 per month
• Rivastigmine capsules — only pennies per dose; the rivastigmine patch (9.5–13.3 mg/24h) runs about $52–$56 per month
• Memantine 10 mg — about $2–$4 per month
• Carbidopa/levodopa 25-100 three times daily — about $7 per month
• Melatonin — a low-cost over-the-counter supplement
• Clonazepam and low-dose quetiapine — under $1 per month each
• Pimavanserin (Nuplazid) is the exception: a brand-only drug at roughly $5,100 per month (about $170 per 34 mg capsule, CMS NADAC).

Coverage path. The generics above are almost always covered as lowest-tier (Tier 1) medicines with the smallest copay under Medicare Part D and Medicaid. If you are uninsured, ask the pharmacy about its flat-rate generic list or compare a discount-card cash price (for example GoodRx). For Nuplazid, ask the prescriber’s office about the manufacturer copay-savings and patient-assistance program (Acadia Connect) and expect a prior authorization; Medicare beneficiaries can ask about the Part D Extra Help / Low-Income Subsidy.

Prices are pharmacy acquisition costs (CMS NADAC, July 15, 2026 file) for a typical 30-day supply and will change over time; confirm current pricing with your pharmacy.

A fuller cost picture, drug by drug (about $1–$2 for donepezil, $2–$4 for memantine, $7 for carbidopa/levodopa, roughly $52–$56 for the rivastigmine patch, under $1 each for clonazepam and quetiapine, about $10–$15 for a month of midodrine, and roughly $5,100 for brand Nuplazid), appears in the Medication Reference section that follows.

💊 Medication Reference — Doses, Titration, and Stop Rules

This section collects the specific, label-based numbers a family most often asks for — starting doses, how the dose is raised, what to watch for, and the point at which a medicine should be paused or stopped. These are reference figures from FDA prescribing information and major guidelines, not a prescription. Only your neurologist can set your actual doses. Bring this section to your appointment and go through it together. Every dose below is what appears on the U.S. FDA label or in the DLB Consortium (McKeith 2017), AASM, and Movement Disorder Society guidance current as of 2026.

Rivastigmine (Exelon) — strongest cholinesterase-inhibitor evidence in Lewy body disease

FDA-approved for mild-to-moderate Parkinson's disease dementia; used off-label for DLB. Per the FDA label (Exelon prescribing information):

• Capsules: start 1.5 mg twice daily. If tolerated after at least 4 weeks, step up to 3 mg twice daily, then 4.5 mg twice daily, then a maximum of 6 mg twice daily (12 mg/day total). Raise the dose no more often than every 4 weeks, and always with food to reduce nausea.
• Transdermal patch (preferred for tolerability): start 4.6 mg/24h, increase after at least 4 weeks to 9.5 mg/24h, and if needed to a maximum of 13.3 mg/24h. Rotate the site daily and never wear two patches at once.
• Monitor: nausea, vomiting, weight loss, slow heart rate (bradycardia), and fainting. The FDA label specifically warns that parkinsonian tremor can worsen.
• Stop rule: if a patient stops rivastigmine for more than several days, do NOT restart at the old dose — re-titrate from 1.5 mg BID or the 4.6 mg patch, because restarting high can cause severe vomiting. Discontinue if there is intractable vomiting, significant weight loss, or symptomatic bradycardia, and taper rather than stopping abruptly — abrupt withdrawal can cause a rapid, sometimes irreversible cognitive drop.

Evidence: Emre et al., rivastigmine for PDD, N Engl J Med 2004;351:2509. Cost: capsules are pennies per dose; the patch runs about $52–$56 per month (CMS NADAC). Ask: "Would the rivastigmine patch at 4.6 mg per 24 hours be easier on my stomach than the capsules?"

Donepezil (Aricept)

• Start 5 mg once daily at bedtime; after 4–6 weeks may increase to 10 mg once daily. (The 23 mg strength is for severe Alzheimer's and is not used in LBD.)
• In Japan, donepezil is specifically approved for DLB (2014) at up to 10 mg daily — the only DLB-specific cholinesterase-inhibitor approval in the world.
• Monitor: nausea, diarrhea, vivid dreams or nightmares (give in the morning if this happens), bradycardia, and muscle cramps.
• Stop rule: taper, do not stop suddenly. Discontinue if bradycardia is symptomatic or GI effects are intolerable. Cost about $1–$2 per month.

Ask: "If donepezil gives me nightmares, can I take the 5 mg in the morning instead of at night?"

Galantamine (Razadyne)

• Immediate-release: start 4 mg twice daily, target 8–12 mg twice daily; extended-release capsule: start 8 mg once daily, target 16–24 mg once daily. Less studied in LBD than rivastigmine or donepezil but a reasonable alternative.
• Monitor and stop as for the other cholinesterase inhibitors (GI effects, bradycardia); re-titrate if a dose is missed for 3 or more days.

Memantine (Namenda)

• NMDA-receptor antagonist, added to (not replacing) a cholinesterase inhibitor in moderate-to-advanced disease. Immediate-release: start 5 mg once daily and increase by 5 mg each week to a target of 10 mg twice daily (20 mg/day). Extended-release: start 7 mg and titrate to 28 mg once daily.
• Monitor: dizziness, confusion, and — importantly in DLB — any worsening of hallucinations.
• Stop rule: discontinue if hallucinations or agitation worsen after it is started; the DLB evidence is mixed, so it earns its place only if it clearly helps. Cost about $2–$4 per month.

Carbidopa/Levodopa (Sinemet) — for parkinsonism, used cautiously

• Typical start: one-half to one 25/100 mg immediate-release tablet (carbidopa/levodopa) three times daily, raised slowly. Many people with DLB get only a partial motor response and reach a ceiling far below typical Parkinson's doses.
• Avoid dopamine agonists (pramipexole, ropinirole, rotigotine), amantadine, and anticholinergics for tremor — all worsen hallucinations and confusion in LBD.
• Stop rule: when to stop escalating — if hallucinations, delusions, or daytime sleep attacks emerge as the dose rises, step back to the last dose that did not cause them and hold there; never stop levodopa abruptly (risk of a parkinsonism-hyperpyrexia/neuroleptic-malignant-like crisis).

Cost about $7 per month. Ask: "What is the lowest carbidopa/levodopa dose worth trying for my stiffness, and at what point do we stop increasing it?"

Pimavanserin (Nuplazid) — the safest antipsychotic-class option

• Selective serotonin (5-HT2A) inverse agonist that does not block dopamine, so it does not worsen parkinsonism. FDA-approved in 2016 for hallucinations and delusions of Parkinson's disease psychosis; used off-label for DLB.
• Dose is fixed at 34 mg once daily (two 17 mg capsules or one 34 mg capsule); no titration. Full effect can take 4–6 weeks.
• Regulatory note (accuracy matters): the HARMONY relapse-prevention trial was positive (hazard ratio 0.35), but the FDA issued a Complete Response Letter and did not approve pimavanserin for the broader "dementia-related psychosis" indication. Its only approved use remains Parkinson's disease psychosis. DLB use is therefore off-label.
• Monitor: QT-interval prolongation (avoid combining with other QT-prolonging drugs), swelling, and confusion. Stop rule: discontinue if the QTc is prolonged or if there is no benefit after 6 weeks.

Cost is the outlier: roughly $5,100 per month (about $170 per capsule, CMS NADAC); ask the prescriber about the Acadia Connect patient-assistance program. Ask: "Is pimavanserin at 34 mg a day an option for my hallucinations, and will my heart rhythm be checked first?"

Quetiapine (Seroquel), very low dose — only if pimavanserin is not available

• Of the older antipsychotics, quetiapine has the least dopamine-blocking activity. If it must be used, start extremely low: 12.5 mg to 25 mg at bedtime, rarely up to 50 mg, with close watching for sedation, worsening parkinsonism, and blood-pressure drops.
• Stop rule: discontinue immediately and call the neurologist if there is a jump in rigidity, fever, confusion, or a fall — these can signal a neuroleptic-sensitivity reaction even with quetiapine. Cost under $1 per month.

Melatonin — first-line for REM sleep behavior disorder (RBD)

• The American Academy of Sleep Medicine recommends melatonin as a first-line RBD treatment. Start 3 mg at bedtime and increase gradually toward 6–12 mg as needed; side effects are usually mild (morning grogginess, headache).
• Why it is preferred in LBD: it lacks the sedation, fall risk, and confusion that benzodiazepines can cause. Low-cost over-the-counter supplement.

Ask: "Can we try melatonin at 3 mg and work up to 6 to 12 mg for the dream-acting before anything stronger?"

Clonazepam — second-line for RBD, used with caution

• Low dose only: 0.25 mg to 1 mg at bedtime. Effective for dream-enactment but risky in LBD because it can deepen confusion, worsen daytime sleepiness, and increase falls.
• Stop rule: discontinue (by tapering) if there is daytime drowsiness, new confusion, or a fall; reserve for RBD that melatonin alone does not control. Cost under $1 per month.

Orthostatic hypotension medicines (for blood-pressure drops on standing)

• Midodrine: 2.5 mg to 10 mg up to three times daily during waking hours; do not dose within 4 hours of lying down (supine-hypertension risk). About $10–$15 per month.
• Droxidopa (Northera): FDA-approved for neurogenic orthostatic hypotension. Start 100 mg three times daily and titrate in 100 mg steps every 24–48 hours to a maximum of 600 mg three times daily; the last dose at least 3 hours before bed. Effectiveness beyond 2 weeks is not established, per the FDA label — reassess.
• Fludrocortisone: 0.1 mg to 0.2 mg daily; watch for leg swelling, low potassium, and supine hypertension.
• Stop rule for all three: check blood pressure lying and standing; discontinue or lower the dose if supine (lying) blood pressure climbs too high or swelling develops.

Ask: "Should my blood pressure be measured both lying down and standing, and would midodrine or droxidopa help my dizziness?"

Bladder, mood, and constipation (choose the LBD-safe option)

• Overactive bladder: prefer mirabegron 25–50 mg daily over oxybutynin, which is anticholinergic and worsens cognition in LBD.
• Depression: SSRIs are first-line — for example sertraline 25–50 mg to start, escitalopram 5–10 mg, or citalopram 10–20 mg. Avoid tricyclic antidepressants (anticholinergic).
• Constipation: polyethylene glycol (MiraLAX) 17 g in water daily; increase fiber and fluids; avoid long-term stimulant laxatives.

💬 Scripts for Your Care Team — Say It Word for Word

Appointments are short and LBD is complex. These are ready-made sentences you can read aloud (or hand over) to make sure the most important points are covered. They are grouped by situation.

Protecting against the antipsychotic danger

• Ask: "I have Lewy body dementia and severe neuroleptic sensitivity — please do not give haloperidol, risperidone, olanzapine, or any antipsychotic without calling my neurologist first."
• Ask: "Will you flag severe neuroleptic sensitivity as an allergy in my chart and list the specific drugs to avoid?"
• Ask: "For nausea, can you use ondansetron instead of metoclopramide or prochlorperazine, which block dopamine?"

Getting the diagnosis right

• Ask: "Could this be Lewy body dementia rather than Alzheimer's, and would a DaTscan help tell them apart?"
• Ask: "Is the alpha-synuclein seed amplification assay available here, or should I be referred somewhere that offers it?"
• Ask: "Should I have a sleep study to confirm REM sleep behavior disorder?"
• Ask: "Can you refer me to a movement-disorder or behavioral neurologist experienced with Lewy body disease?"

Starting and judging treatment

• Ask: "Should I start a cholinesterase inhibitor, and would the rivastigmine patch be gentler than capsules?"
• Ask: "How long should we give this medicine before we decide whether it is working?"
• Ask: "If I ever stop my cholinesterase inhibitor, could my thinking drop quickly, and how do we taper safely?"
• Ask: "Is memantine worth adding at my stage, and what would tell us it is not helping?"

Symptoms that frighten families

• Ask: "My hallucinations are distressing — is pimavanserin an option, and will my heart rhythm be checked first?"
• Ask: "What exactly should we do if there is a behavioral crisis at home in the middle of the night?"
• Ask: "What bedroom-safety steps do you recommend so the dream-acting does not cause injury?"
• Ask: "Should my blood pressure be checked lying and standing to explain these dizzy spells and falls?"

Planning ahead

• Ask: "While I can still take part, can you help me complete advance directives and name a healthcare power of attorney?"
• Ask: "Am I eligible for any Lewy body dementia clinical trial, or a biomarker or brain-donation study?"

Key Developments in LBD

While there is no cure for LBD, the understanding and management of the disease has improved significantly in recent years. Here are the most important developments:

Getting Diagnosed — Why It Matters So Much

An accurate diagnosis of LBD is critically important because it directly determines which medications are safe, which are dangerous, and what symptoms to expect. Misdiagnosis as Alzheimer’s disease can lead to the prescription of antipsychotics that can be devastating in LBD. Misdiagnosis as pure Parkinson’s disease can mean cognitive and psychiatric symptoms are overlooked.

Core and Suggestive Features of DLB

The Fourth Consensus Criteria (McKeith 2017) define four core clinical features and several suggestive and supportive features. Probable DLB requires dementia plus two or more core features, or one core feature plus one or more indicative biomarkers.

DLB vs. Parkinson’s Disease Dementia — Does It Matter?

DLB and PDD are caused by the same underlying pathology (Lewy bodies) and share many symptoms. The clinical distinction is based on the “one-year rule”:

• DLB: Cognitive symptoms appear before or within one year of parkinsonism.
• PDD: Parkinson’s disease motor symptoms have been present for at least one year before dementia develops.

For treatment purposes, DLB and PDD are managed very similarly. Cholinesterase inhibitors help both. The same antipsychotic cautions apply to both. The same motor symptom treatments are used. Where differences exist, they are noted in the treatment sections below.

Treating Cognitive Symptoms

Cognitive symptoms in LBD include problems with attention, executive function (planning, organizing, problem-solving), visuospatial abilities, and eventually memory. Fluctuating cognition — good days and bad days, or even good and bad hours — is a hallmark of the disease.

Managing Motor Symptoms (Parkinsonism)

Many people with LBD develop motor symptoms similar to Parkinson’s disease: slowness (bradykinesia), stiffness (rigidity), tremor, shuffling gait, and postural instability. Motor symptoms in DLB tend to be less responsive to levodopa than in typical Parkinson’s disease, and the risk of exacerbating psychiatric symptoms is higher.

Managing Psychiatric Symptoms

Psychiatric symptoms are among the most challenging aspects of LBD for patients and caregivers. They include visual hallucinations, delusions, agitation, anxiety, depression, and apathy.

Managing Sleep Disorders

Sleep disturbances are nearly universal in LBD and cause significant burden for both patients and caregivers.

Managing Autonomic Dysfunction

The autonomic nervous system — which controls blood pressure, digestion, bladder function, and temperature regulation — is commonly affected in LBD.

Medications to Avoid in LBD

Clinical Trials — Finding and Enrolling

Clinical trials are particularly important in LBD because there is no disease-modifying therapy yet approved. Trials offer access to investigational treatments and help advance the understanding of this disease.

International Access & Regulatory Landscape

LBD drug availability and diagnostic tools vary significantly by country. Here is an overview of key international differences:

Failed & De-Adopted Therapies

Knowing what has been tried and did not work is important. Understanding past failures helps you evaluate new options and avoid treatments that have already been studied and found to be ineffective or harmful.

Specialty Centers

LBD outcomes and quality of life are significantly better when managed by clinicians experienced in Lewy body disorders. A second opinion from a movement disorder or cognitive neurology center is strongly recommended.

Caregiver Guidance

Caring for someone with LBD is among the most demanding forms of caregiving. The combination of cognitive fluctuations, visual hallucinations, motor disability, sleep disturbances, and behavioral changes creates challenges that are different from and often more complex than Alzheimer’s disease caregiving.

Reproductive-Age Considerations & Lewy Body Dementia

Lewy body dementia predominantly affects adults over 65 and is exceptionally rare in people of reproductive age. Pregnancy concurrent with LBD is not a recognized clinical scenario. However, the following information is relevant for younger caregivers and for rare younger-onset cases.

Medication safety for pregnant caregivers

Family members or caregivers who are pregnant and who handle LBD medications should take precautions:

• Rivastigmine patches (Exelon) — avoid skin contact with the patch during pregnancy; wear gloves when applying or removing. Accidental skin absorption is a theoretical risk.
• Clonazepam — a known teratogen (benzodiazepine); pregnant caregivers should not handle crushed or split tablets without gloves, and should ensure safe storage.
• Levodopa-carbidopa — animal data suggest potential fetal harm; pregnant caregivers handling these medications should avoid crushing tablets (dust inhalation).

Genetic counseling for family members

LBD has both sporadic and genetic forms. Family members of reproductive age who are concerned about their own risk may consider genetic counseling, particularly if there is a strong family history of LBD or Parkinson disease. Relevant genes include GBA (glucocerebrosidase) and SNCA (alpha-synuclein). Genetic counseling through the University of Utah Department of Neurology or Huntsman Cancer Institute is available; ask your neurologist for a referral.

Glossary

Alpha-synuclein

A protein that misfolds and accumulates in Lewy bodies, the pathological hallmark of LBD and Parkinson’s disease.

Autonomic dysfunction

Failure of the autonomic nervous system, causing problems with blood pressure, digestion, bladder control, and temperature regulation.

Bradykinesia

Slowness of movement, a cardinal feature of parkinsonism.

Capgras syndrome

A delusion that a family member or caregiver has been replaced by an identical impostor. Common in LBD.

Cholinesterase inhibitor

A class of drugs (rivastigmine, donepezil, galantamine) that increase acetylcholine levels in the brain. First-line treatment for LBD cognitive symptoms.

Cognitive fluctuations

Spontaneous, unpredictable variations in attention and alertness, often occurring over hours or days. A core feature of DLB.

DaTscan

A nuclear medicine imaging test that measures dopamine transporter levels. Reduced uptake supports a diagnosis of DLB or Parkinson’s disease.

DLB

Dementia with Lewy bodies. The form of LBD where cognitive symptoms appear before or within one year of motor symptoms.

Dopamine

A brain chemical important for movement, motivation, and reward. Depleted in Parkinson’s disease and LBD.

GBA

Glucocerebrosidase gene. Variants in GBA increase risk for Parkinson’s disease and LBD.

Lewy bodies

Abnormal clumps of alpha-synuclein protein found inside neurons in the brains of people with LBD and Parkinson’s disease.

MIBG scintigraphy

A nuclear medicine test that measures sympathetic nerve function in the heart. Reduced uptake supports a Lewy body diagnosis.

Neuroleptic sensitivity

An exaggerated and potentially life-threatening adverse reaction to antipsychotic medications, characteristic of LBD.

Orthostatic hypotension

A drop in blood pressure upon standing, causing dizziness and risk of falls. Common in LBD.

Parkinsonism

Motor symptoms resembling Parkinson’s disease: bradykinesia, rigidity, tremor, and postural instability.

PDD

Parkinson’s disease dementia. Dementia developing in a person with established Parkinson’s disease (motor symptoms preceding cognitive symptoms by at least one year).

Pimavanserin (Nuplazid)

A selective serotonin inverse agonist approved for Parkinson’s disease psychosis. Does not block dopamine. The safest antipsychotic option for LBD.

RBD (REM sleep behavior disorder)

A sleep disorder where the normal paralysis during REM sleep is absent, causing people to physically act out vivid dreams.

Rivastigmine (Exelon)

A cholinesterase inhibitor with the strongest evidence for cognitive and behavioral symptoms in LBD. Available as a patch or capsule.

SAA (seed amplification assay)

A laboratory test that detects misfolded alpha-synuclein in cerebrospinal fluid with high accuracy for diagnosing synucleinopathies.

Synucleinopathy

A group of diseases characterized by abnormal alpha-synuclein accumulation, including Parkinson’s disease, DLB, PDD, and multiple system atrophy.

Visuospatial dysfunction

Difficulty perceiving spatial relationships, judging distances, navigating, or recognizing objects. Prominent early in DLB.

Sources and Further Reading

This guide draws on published medical literature, clinical trial records, and the work of physicians and researchers treating and studying Lewy body dementia across multiple countries. Key sources are listed below.

Primary Resources

• PubMed (pubmed.ncbi.nlm.nih.gov) — Free public database of medical research
• ClinicalTrials.gov (clinicaltrials.gov) — Authoritative registry of clinical trials
• Lewy Body Dementia Association (LBDA) (lbda.org) — Patient education, caregiver support, research updates (1-800-539-9767)
• National Institute on Aging (NIA) (nia.nih.gov) — Comprehensive LBD information
• Alzheimer’s Association (alz.org) — LBD information and 24/7 helpline (1-800-272-3900)
• Lewy Body Society (UK) (lewybody.org) — UK patient and carer resources
• Michael J. Fox Foundation (michaeljfox.org) — Parkinson’s and related disorders research

Key Guideline and Trial References

• Fourth Consensus DLB Criteria: McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88–100.
• NICE NG97: Dementia — assessment, management and support for people living with dementia and their carers. National Institute for Health and Care Excellence.
• MDS PDD Criteria: Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Movement Disorders. 2007;22(12):1689–1707.
• PASADENA: Pagano G, Taylor KI, Anzures-Cabrera J, et al. Trial of prasinezumab in early-stage Parkinson’s disease. N Engl J Med. 2022;387(5):421–432. (NCT03100149)
• SPARK (cinpanemab): Lang AE, Siderowf AD, Macklin EA, et al. Trial of cinpanemab in early Parkinson’s disease. N Engl J Med. 2022;387(5):408–420. (NCT03318523)
• HARMONY (pimavanserin): Tariot PN, Cummings JL, Soto-Martin ME, et al. Trial of pimavanserin in dementia-related psychosis. N Engl J Med. 2021;385(4):309–319. (NCT03325556)
• Rivastigmine in PDD: Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med. 2004;351(24):2509–2518.
• Alpha-synuclein SAA: Siderowf A, Concha-Marambio L, Lafontant DE, et al. Assessment of heterogeneity among participants in the Parkinson’s Progression Markers Initiative cohort using alpha-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 2023;22(5):407–417.

Key Search Terms for ClinicalTrials.gov and PubMed

What This Guide Does Not Know

An honest guide names its own limits:

• This guide cannot diagnose or treat anyone. It does not know your specific symptoms, biomarker results, medication history, or personal preferences. Only your medical team can build an actual plan.
• LBD research is evolving. New diagnostic tools, trial results, and treatment approaches emerge regularly. Every time-sensitive fact should be re-verified with your team and primary sources.
• Drug availability varies by country. This guide discusses medications available in multiple countries but focuses on the United States. Access differs in Europe, Asia, Canada, and other regions.
• Individual experiences vary enormously. Some people with LBD live well for many years; others decline more rapidly. Prognostic estimates describe populations, not individuals.
• Care is not equal everywhere. This guide describes best practices at well-resourced academic centers. Referral to a movement disorder or cognitive neurology specialist is often the single highest-value step a patient can take.